<?xml version="1.0" encoding="UTF-8"?>
<list list-type="simple">
 <list-item>
  <p>
   <bold>Remdesivir</bold>° 
   <bold>(GS-57324)</bold>, once daily intravenously: 200 mg loading dose, followed by 100 mg daily maintenance dose, during 10 days, or (if Remdesivir not available)
  </p>
  <p>
   <bold>Lopinavir/ritonavir</bold>* 200/50 mg tablets, 2 tablets q12h, during 14 days and
  </p>
  <p>
   <bold>Hydroxychloroquine phosphate **</bold>400 mg tablets, 1 tablet q12 as loading dose, followed by 200 mg tablets, 1 tablet q12, during 10 days, or
  </p>
  <p>
   <bold>Chloroquine phosphate**</bold> 250 mg tablets, 2 tablet q12, during 10 days and
  </p>
  <p>
   <bold>Tocilizumab</bold>^ 8 mg/kg (maximum 800 mg/dose), single dose intravenously (1- hour infusion); in absence or with poor clinical improvement a second dose should be administered after 8-12 hours
  </p>
 </list-item>
 <list-item>
  <p>* Alternatively to Lopinavir/ritonavir, 
   <bold>Darunavir</bold> 600 mg tablets, 1 tablet q12 plus 
   <bold>Ritonavir</bold> 100 mg tablets, 1 tablet q12, during 14 days.
  </p>
 </list-item>
 <list-item>
  <p>** Before chloroquine and hydrossichloroquine administration, G6PD deficiency test should be performed</p>
 </list-item>
 <list-item>
  <p>° Do not co-administrate Remdesivir with lopinavir/ritonavir, due to possible drug interactions</p>
 </list-item>
 <list-item>
  <p>^ Tocilizumab administration should be guided by the following selection criteria: a) PaO2/Fi02 ratio &lt;300 mmHg; b) rapid worsening of respiratory gas exchange with or without availability of non-invasive or invasive ventilation; d) IL-6 levels &gt;40 pg/mL (if not available, see D-dimer levels &gt;1000 ng/mL.</p>
 </list-item>
</list>
